News and Announcements
Kazia Therapeutics Limited (ASX: KZA) releases September investor newsletter
- Published September 25, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide its latest investor newsletter.
Key topics in this newsletter include:
- An update on activity since the last newsletter was released in June 2019
- An overview of the ANZ Leadership Forum awards, where Kazia was proud to be named a winner
- Details of the six clinical trials we are currently involved in
- A research update on GDC-0084 used in combination with arsenic trioxide
- Details of a poster presented at AACR summarizing data from Part A of our Cantrixil Phase I trial
- Details of a poster presented at EANO outlining the ongoing Phase II study of GDC0084 in glioblastoma
- Information on progress being made in DIPG following on from the work performed by Professor Matt Dun
- Some novel analytical methods used by St Jude Children’s Research Hospital to measure concentration of GDC-0084 in biological samples The newsletter also provides a summary of recent and coming events.
Investors can access the newsletter via the Kazia Therapeutics website at the following link: https://www.kaziatherapeutics.com/mediacentre/insight/september-2019-shareholder-newsletter
For more information on Kazia register your interest below.
Company Updates
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
The Great Convergence: The $19 Trillion Shift Defining the Next Era of Wealth
A quiet but powerful trend is re-architecting global finance: the great convergence of traditional finance and digital assets. With Boston Consulting Group forecasting the tokenized real-world assets market to hit $16 trillion by 2030, this isn’t speculation—it’s a new institutional reality. Discover the infrastructure being built, the power of tokenization, and how mature DeFi strategies are defining the next era of wealth.
Beyond the Grandstand: Why Australian Sport is the New Asset Class for Family Offices
Australian sport is evolving into a compelling, institutional-grade asset class. Driven by a “golden decade” of major events and significant private capital, it offers high-growth, uncorrelated returns, making it an attractive new frontier for savvy family offices.
Backed By Leading Investment Groups and Family Offices
